providers and the need to limit text, the current guideline format delineates that each recommendation be supported by limited text (ideally, <250 words) and hyperlinks to supportive evidence summary tables. Ongoing efforts to further limit text are underway. Recognizing the importance of cost-value considerations in certain guidelines, when appropriate and feasible, an analysis of the value of a drug, device, or intervention may be performed in accordance with the ACC/AHA methodology (3).
To ensure that guideline recommendations remain current, new data are reviewed on an ongoing basis, with full guideline revisions commissioned in approximately 6-year cycles.
Publication of new, potentially practice-changing study results that are relevant to an existing or new drug, device, or management strategy will prompt evaluation by the Task Force, in consultation with the relevant guideline writing committee, to determine whether a focused update should be commissioned. For additional information and policies regarding guideline development, we encourage readers to consult the ACC/AHA guideline methodology manual (4) and other methodology articles (5-8).
Selection of Writing Committee Members
The Task Force strives to avoid bias by selecting experts from a broad array of backgrounds. Writing committee members represent different geographic regions, sexes, ethnicities, races, intellectual perspectives/biases, and scopes of clinical practice. The Task Force may also invite organizations and professional societies with related interests and expertise to participate as partners, collaborators, or endorsers.
Relationships With Industry and Other Entities
The ACC and AHA have rigorous policies and methods to ensure that guidelines are developed without bias or improper influence. The complete relationships with industry and other entities (RWI) policy can be found online. Appendix 1 of the current document lists writing committee members' relevant RWI. For the purposes of full transparency, writing committee members' comprehensive disclosure information is available online, as is comprehensive disclosure information for the Task Force.
Evidence Review and Evidence Review Committees
When developing recommendations, the writing committee uses evidence-based methodologies that are based on all available data (4-7). Literature searches focus on randomized controlled trials (RCTs) but also include registries, nonrandomized comparative and descriptive studies, case series, cohort studies, systematic reviews, and expert opinion. Only key references are cited. .
Guideline-Directed Management and Therapy
The term guideline-directed management and therapy 
Class of Recommendation and Level of Evidence
The Class of Recommendation (COR) indicates the strength of the recommendation, encompassing the estimated magnitude and certainty of benefit in proportion to risk. The Level of Evidence (LOE) rates the quality of scientific evidence that supports the intervention on the basis of the type, quantity, and consistency of data from clinical trials and other sources ( Table 1 ) (4-6).
The reader is encouraged to consult the full-text 1. INTRODUCTION
Methodology and Evidence Review
The recommendations listed in this guideline are, whenever possible, evidence based. An initial extensive evidence review, which included literature derived from research involving human subjects, published in English, and indexed in MEDLINE (through PubMed), EMBASE, the Cochrane Library, the Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline, was conducted from July to October 2015. Key search words included but were not limited to the following: athletes, autonomic neuropathy, bradycardia, carotid sinus hypersensitivity, carotid sinus syndrome, children, death, dehydration, diagnosis, driving, electrocardiogram, electrophysiological study, epidemiology, Shen et al. Syncope" is published in conjunction with this guideline (10).
Organization of the Writing Committee
The writing committee was composed of clinicians with expertise in caring for patients with syncope, including cardiologists, electrophysiologists, an emergency physician, and a pediatric cardiologist. The writing committee included representatives from the ACC, AHA, Heart Rhythm Society (HRS), American Academy of Neurology, American College of Emergency Physicians, and Society for Academic Emergency Medicine. 
Document Review and Approval

Scope of the Guideline
The purpose of this ACC/AHA/HRS guideline is to provide contemporary, accessible, and succinct guidance on the older populations has been evolving. Age >75 years is used to define older populations or older adults in this document, unless otherwise specified. If a study has defined older adults by a different age cutoff, the relevant age is noted in those specific cases. Finally, the guideline addresses the management of syncope with the patient as a focus, rather than larger aspects of health services, such as syncope management units. The goals of the present guideline are:
n To define syncope as a symptom, with different causes, in different populations and circumstances.
n To provide guidance and recommendations on the evaluation and management of patients with suspected syncope in the context of different clinical settings, specific causes, or selected circumstances.
n To identify key areas in which knowledge is lacking, to foster future collaborative research opportunities and efforts.
In developing this guideline, the writing committee reviewed the evidence to support recommendations in the relevant ACC/AHA guidelines noted in Table 2 (in the full-text guideline) and affirms the ongoing validity of the related recommendations in the context of syncope, thus obviating the need to repeat existing guideline recommendations in the present guideline when applicable or when appropriate.
GENERAL PRINCIPLES
For the purpose of this guideline, definitions of syncope and relevant terms are provided in Table 2 . See Table 3 for historical characteristics associated with, although not diagnostic, cardiac and noncardiac syncope; Table 4 for short-and long-term risk factors; Table 5 for the type of events, event rates, and study durations from investigations that estimate risk scores; Table 6 for examples of serious conditions associated with syncope which may require inpatient evaluation and "treatment"; Figure 1 for the algorithm on initial evaluation for syncope; and Figure 2 
Loss of consciousness
A cognitive state in which one lacks awareness of oneself and one's situation, with an inability to respond to stimuli.
Transient loss of consciousness Self-limited loss of consciousness (11) can be divided into syncope and nonsyncope conditions. Nonsyncope conditions include but are not limited to seizures, hypoglycemia, metabolic conditions, drug or alcohol intoxication, and concussion due to head trauma. The underlying mechanism of syncope is presumed to be cerebral hypoperfusion, whereas nonsyncope conditions are attributed to different mechanisms.
Presyncope (near-syncope)
The symptoms before syncope. These symptoms could include extreme lightheadedness; visual sensations, such as "tunnel vision" or "graying out"; and variable degrees of altered consciousness without complete loss of consciousness. Presyncope could progress to syncope, or it could abort without syncope.
Unexplained syncope (syncope of undetermined etiology)
Syncope for which a cause is undetermined after an initial evaluation that is deemed appropriate by the experienced healthcare provider. The initial evaluation includes but is not limited to a thorough history, physical examination, and ECG.
Orthostatic intolerance
A syndrome consisting of a constellation of symptoms that include frequent, recurrent, or persistent lightheadedness, palpitations, tremulousness, generalized weakness, blurred vision, exercise intolerance, and fatigue upon standing. These symptoms can occur with or without orthostatic tachycardia, OH, or syncope (12). Individuals with orthostatic intolerance have $1 of these symptoms associated with reduced ability to maintain upright posture.
Orthostatic tachycardia
A sustained increase in heart rate of $30 bpm within 10 min of moving from a recumbent to a quiet (nonexertional) standing position (or $40 bpm in individuals 12-19 y of age) (11-13).
Orthostatic hypotension (OH)
A drop in systolic BP of $20 mm Hg or diastolic BP of $10 mm Hg with assumption of an upright posture (13).
n Initial (immediate) OH A transient BP decrease within 15 s after standing, with presyncope or syncope (13,14).
n Classic OH A sustained reduction of systolic BP of $20 mm Hg or diastolic BP of $10 mm Hg within 3 min of assuming upright posture (13).
n Delayed OH A sustained reduction of systolic BP of $20 mm Hg (or 30 mm Hg in patients with supine hypertension) or diastolic BP of $10 mm Hg that takes >3 min of upright posture to develop. The fall in BP is usually gradual until reaching the threshold (13).
n Neurogenic OH A subtype of OH that is due to dysfunction of the autonomic nervous system and not solely due to environmental triggers (such as dehydration or drugs) (15,16). Neurogenic OH is due to lesions involving the central or peripheral autonomic nerves.
Cardiac (cardiovascular) syncope
Syncope caused by bradycardia, tachycardia, or hypotension due to low cardiac index, blood flow obstruction, vasodilatation, or acute vascular dissection (17,18).
Noncardiac syncope
Syncope due to noncardiac causes, which includes reflex syncope, OH, volume depletion, dehydration, and blood loss (17).
Reflex (neurally mediated) syncope Syncope due to a reflex that causes vasodilation, bradycardia, or both (11-13).
n Vasovagal syncope (VVS)
The most common form of reflex syncope mediated by the vasovagal reflex. VVS: 1) may occur with upright posture (standing or seated or with exposure to emotional stress, pain, or medical settings; 2) typically is characterized by diaphoresis, warmth, nausea, and pallor; 3) is associated with vasodepressor hypotension and/or inappropriate bradycardia; and 4) is often followed by fatigue. Typical features may be absent in older patients (12). VVS is often preceded by identifiable triggers and/or by a characteristic prodrome. The diagnosis is made primarily on the basis of a thorough history, physical examination, and eyewitness observation, if available.
n Carotid sinus syndrome Reflex syncope associated with carotid sinus hypersensitivity (11). Carotid sinus hypersensitivity is present when a pause $3 s and/or a decrease of systolic pressure $50 mm Hg occurs upon stimulation of the carotid sinus. It occurs more frequently in older patients. Carotid sinus hypersensitivity can be associated with varying degrees of symptoms. Carotid sinus syndrome is defined when syncope occurs in the presence of carotid sinus hypersensitivity.
(continued on the next page)
Definitions: Terms and Classification
Shen et al.
Epidemiology and Demographics
Studies of syncope report prevalence rates as high as 41%, with recurrent syncope occurring in 13.5% (25 
Postural (orthostatic) tachycardia syndrome (POTS)
A clinical syndrome usually characterized by all of the following: 1) frequent symptoms that occur with standing (e.g., lightheadedness, palpitations, tremulousness, generalized weakness, blurred vision, exercise intolerance, and fatigue); and 2) an increase in heart rate of $30 bpm during a positional change from supine to standing (or $40 bpm in those 12-19 y of age); and 3) the absence of OH (>20 mm Hg reduction in systolic BP). Symptoms associated with POTS include those that occur with standing (e.g., lightheadedness, palpitations); those not associated with particular postures (e.g., bloating, nausea, diarrhea, abdominal pain); and those that are systemic (e.g., fatigue, sleep disturbance, migraine headaches) (19). The standing heart rate is often >120 bpm (13,20-24).
Psychogenic pseudosyncope A syndrome of apparent but not true loss of consciousness that may occur in the absence of identifiable cardiac, reflex, neurological, or metabolic causes (11).
*These definitions are derived from previously published definitions from scientific investigations, guidelines, expert consensus statements, and Webster dictionary after obtaining consensus from the WC BP indicates blood pressure; ECG, electrocardiogram; OH, orthostatic hypotension; POTS, postural tachycardia syndrome; and VVS, vasovagal syncope. 
FIGURE 1 Syncope Initial Evaluation
ADDITIONAL EVALUATION AND DIAGNOSIS
See Figure 3 for additional evaluation and diagnosis for syncope and Table 7 for a summary of types of ambulatory cardiac rhythm monitoring devices. See Online Data Supplements 7 to 16 for data supporting Section 3. Table 1 .
*Applies to patients after a normal initial evaluation without significant injury or cardiovascular morbidities; patients followed up by primary care physician as needed. †In selected patients (see Section 1.4).
CT indicates computed tomography; CV, cardiovascular; ECG, electrocardiogram; EPS, electrophysiological study; MRI, magnetic resonance imaging; OH, orthostatic hypotension; and TTE, transthoracic echocardiography.
Recommendations for Blood Testing COR LOE RECOMMENDATIONS
IIa B-NR Targeted blood tests are reasonable in the evaluation of selected patients with syncope identified on the basis of clinical assessment from history, physical examination, and ECG (82).
IIb C-LD
Usefulness of brain natriuretic peptide and high-sensitivity troponin measurement is uncertain in patients for whom a cardiac cause of syncope is suspected (83-86).
III: No Benefit B-NR
Routine and comprehensive laboratory testing is not useful in the evaluation of patients with syncope (87,88).
Blood Testing: Recommendations
A U G U S T 1 , 2 0 1 7 : 6 2 0 -6 3 n A device that continuously records and stores rhythm data over weeks to months n Patient activated, or auto triggered (e.g., to record asymptomatic arrhythmias) to provide a recording of events antecedent to (3-14 min), during, and after (1-4 min) the triggered event n Newer models are equipped with a cellular phone, which transmits triggered data automatically over a wireless network to a remote monitoring system n Frequent, spontaneous symptoms related to syncope, likely to recur within 2-6 wk External patch recorders (103-105)
n Patch device that continuously records and stores rhythm data, with patient-trigger capability to allow for symptom-rhythm correlation n No leads or wires, and adhesive to chest wall/sternum n Various models record from 2-14 d n Offers accurate means of assessing burden of atrial fibrillation n Patient activated, or auto triggered (e.g., to record asymptomatic arrhythmias) to provide a recording of events antecedent to, during, and after the triggered event n Can be considered as an alternative to external loop recorder n Given that it is leadless, can be accurately selfapplied, and is largely water resistant, it may be more comfortable and less cumbersome than an external loop recorder, potentially improving compliance n Unlike Holter monitors and other external monitors, it offers only 1-lead recording Shen et al.
2017 ACC/AHA/HRS Syncope Guideline: Executive Summary A U G U S T 1 , 2 0 1 7 : 6 2 0 In patients with recurrent VVS, a selective serotonin reuptake inhibitor might be considered (253,259,260).
A U G U S T 1 , 2 0 1 7 : 6 2 0 -6 3 
Options Options
Colors correspond to Class of Recommendation in Table 1 .
VVS indicates vasovagal syncope.
Other Reflex Conditions
Situational syncope is defined as syncope occurring only in certain distinct and usually memorable circumstances, including micturition syncope, defecation syncope, cough syncope, laugh syncope, and swallow syncope (280) (281) (282) (283) (284) (285) (286) .
Appropriate investigations should be undertaken to determine an underlying etiology, including causes that may be reversible (280, (282) (283) (284) (285) . Evidence for treatment is limited mainly to case reports, small case series, and small observational studies (280, (282) (283) (284) (285) Octreotide may be beneficial in patients with syncope and refractory recurrent postprandial or neurogenic OH (320-323). which may or may not meet criteria for OH, and heart rate increase, which may be inadequate or compensatory (8).
Neurogenic Orthostatic Hypotension: Recommendations
The pathophysiology is quite varied. One condition of note is Postural Tachycardia Syndrome (POTS), in which upright posture results in an apparently inappropriate tachycardia, usually with heart rates >120 bpm (9).
Although syncope occurs in patients with POTS, it is relatively infrequent, and there is little evidence that the syncope is due to POTS (9,10). Treatments that improve symptoms of POTS might decrease the occurrence of syncope, although this is unknown (9-19). For further guidance on the management of POTS, we refer readers to the Heart Rhythm Society consensus statement (9). Colors correspond to Class of Recommendation in Table 1 .
BP indicates blood pressure; and OH, orthostatic hypotension.
PSEUDOSYNCOPE: RECOMMENDATIONS
See Online Data Supplements 38 and 39 for data supporting Section 8. 
UNCOMMON CONDITIONS ASSOCIATED WITH SYNCOPE
Athletes: Recommendations
QUALITY OF LIFE AND HEALTHCARE COST OF SYNCOPE
Impact of Syncope on Quality of Life
QoL is reduced with recurrent syncope (397) (398) (399) (400) (401) (402) (403) (404) (405) , as demonstrated in studies that compared patients with and without syncope (399, 405) . QoL associated with recurrent syncope was equivalent to severe rheumatoid arthritis and chronic low-back pain in an adult population (400).
Similarly, pediatric patients with recurrent syncope reported worse QoL than individuals with diabetes mellitus and equivalent QoL to individuals with asthma, end-stage renal disease, and structural heart disease (397).
Healthcare Costs Associated With Syncope
High healthcare costs are associated with the evaluation and management of syncope. These high costs have been estimated both in the United States and abroad.
EMERGING TECHNOLOGY, EVIDENCE GAPS, AND FUTURE DIRECTIONS
The writing committee created a list of key areas in which knowledge gaps are present in the evaluation and management of patients presenting with syncope. These knowledge gaps present opportunities for future research to ultimately improve clinical outcomes and effectiveness of healthcare delivery.
Definition, Classification, and Epidemiology
Reported incidence and prevalence of syncope vary significantly because of several confounders: variable definitions for syncope versus transient loss of consciousness, different populations, different clinical settings, and different study methodologies. Definition and classification of syncope provided in this document will set the standard for future research. Standardized national registries and large sample databases are needed to gather data on a continuous basis to understand the true incidence and prevalence of syncope, understand patient risk, inform driving policies, improve patient outcomes, and improve and streamline health service delivery.
Risk Stratification and Clinical Outcomes
n Studies are needed to determine whether syncope is an independent predictor of nonfatal or fatal outcomes in selected patient populations.
n Studies are needed to develop risk scores to be prospectively validated in a given clinical setting with predefined endpoints from short-and long-term follow-up. n Among patients without identifiable causes of syncope, studies are needed to determine short-and long-term outcomes to guide the overall management of these patients.
Evaluation and Diagnosis
n Studies are needed to better understand the interaction and relationships among the presenting symptom of syncope, the cause of syncope, the underlying disease condition, and their effect on clinical outcomes. Shen et al.
A U G U S T 1 , 2 0 1 7 : 6 2 0 -6 3 2017 ACC/AHA/HRS Syncope Guideline: Executive Summary nonfatal and fatal outcomes and recurrence of syncope are to be included.
n RCTs are needed to determine the features of syncopespecialized facilities that are necessary to achieve beneficial outcomes for patient care and to improve efficiency and effectiveness of healthcare delivery.
n As technology advances, studies are needed to determine the value of new technology in the evaluation and management of patients with syncope. versus "aborted SCD" in patients with inheritable arrhythmic conditions. n Prospectively designed multicenter or national registries are needed to gather clinical information from patients with reflex syncope to better our understanding on other associated conditions, plausible mechanisms, effectiveness of therapeutic interventions, and natural history of these uncommon conditions.
Management of Specific Conditions
n RCTs are needed to continue the identification of effective treatment approaches to patients with recurrent reflex syncope.
Special Populations
n Questions and research about risk stratification, evaluation, and management outlined above for the adult population are needed in the pediatric population, geriatric population, and athletes.
n Prospective national registries and big databases are needed to determine risk associated with driving among different populations with syncope.
n Prospective and randomized studies are needed to assess the usefulness of specialized syncope units in different clinical settings. 
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